These results indicate that conjugation of a HDACi moiety to representative quinolone derivative is a viable approach to generate dual action inhibitors which retain independent HDAC and tubulin polymerization inhibitory activities and have an improved therapeutic activity for cancer therapy. The gene discussed is HDAC9; the disease is cancer.